"A PHASE Ill, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE"

StatusActive
Effective start/end date18/08/1617/08/21

Funding

  • Hoffmann-La Roche Inc.: $117,890.00

Keywords

  • Aging & Alzheimers, Biotechnology & Drug Development